Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-resection/ablation chemotherapy in metastatic colorectal cancer
2020-006144-18Phase 3Active
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Apr 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of fluorouracil, oxaliplatin, folinic acid, irinotecan and capecitabine in metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Progression-free survival. Started Apr 2021; status: active.
02
Drugs
fluorouraciloxaliplatinfolinic acidirinotecancapecitabine
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2020-006144-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-006144-18.